Although lysine acetylation is now recognized as a general protein modification for both histones and non-histone proteins 1-3 , the mechanisms of acetylation-mediated actions are not completely understood. Acetylation of the C-terminal domain (CTD) of p53 (also known as TP53) was an early example of non-histone protein acetylation 4 and its precise role remains unclear. Lysine acetylation often creates binding sites for bromodomain-containing 'reader' proteins 5,6 . Here we use a proteomic screen to identify the oncoprotein SET as a major cellular factor whose binding with p53 is dependent on CTD acetylation status. SET profoundly inhibits p53 transcriptional activity in unstressed cells, but SET-mediated repression is abolished by stress-induced acetylation of p53 CTD. Moreover, loss of the interaction with SET activates p53, resulting in tumour regression in mouse xenograft models. Notably, the acidic domain of SET acts as a 'reader' for the unacetylated CTD of p53 and this mechanism of acetylation-dependent regulation is widespread in nature. For example, acetylation of p53 also modulates its interactions with similar acidic domains found in other p53 regulators including VPRBP (also known as DCAF1), DAXX and PELP1 (refs. 7-9), and computational analysis of the proteome has identified numerous proteins with the potential to serve as acidic domain readers and lysine-rich ligands. Unlike bromodomain readers, which preferentially bind the acetylated forms of their cognate ligands, the acidic domain readers specifically recognize the unacetylated forms of their ligands. Finally, the acetylationdependent regulation of p53 was further validated in vivo by using a knock-in mouse model expressing an acetylation-mimicking form of p53. These results reveal that acidic-domain-containing factors act as a class of acetylation-dependent regulators by targeting p53 and, potentially, other proteins.
acetylated column. Mass spectrometry analysis of this band revealed 28 unique peptides identical to SET ( Fig. 1c and Extended Data Fig. 1a ), an oncoprotein that is activated by translocation-associated gene fusions in patients with acute myeloid leukaemia 14 . Although a previous study reported an interaction between p53 and SET 15 , the impact of CTD acetylation on the functional consequences of this interaction are unclear.
Acetylation-dependent disruption of the p53-SET interaction was confirmed in vitro with purified SET protein ( Fig. 1d ). Moreover, expression of CREB-binding protein (CBP), the enzyme responsible for CTD acetylation, completely abrogated the formation of SET complexes with wild-type p53 (p53 WT ), but not with a CTD acetylation-deficient p53 (p53 KR ) mutant, confirming that CTD acetylation is crucial for the p53-SET interaction in cells ( Fig. 1e) . Notably, other modifications on the CTD lysine residues, including methylation, ubiquitination, sumoylation and neddylation, had no effect on this binding, underscoring the specificity of the acetylation-dependent control of p53-SET interactions (Extended Data Fig. 1b-e ).
Next, we tested whether SET acts as a transcriptional cofactor by forming a p53-SET complex on the p53 target promoter. Although SET alone showed no obvious DNA-binding activity (Fig. 1f ), in the presence of both p53 and SET, a slower-migrating SET/p53-DNA complex was formed and super-shifted by antibodies against p53 or SET. Further binding-domain mapping indicated that the CTD of p53 interacts directly with the acidic domain of SET (Extended Data Fig. 1f-h) . To determine the impact of SET on the transcriptional activity of p53, we measured transactivation of a p53-responsive reporter gene. Indeed, p53-mediated transactivation was abrogated upon co-expression of wild-type SET, but not a SET mutant lacking the acidic domain required for p53 binding (Fig. 1g ). Conversely, wild-type SET-mediated repression was abrogated when a p53 mutant lacking the CTD was expressed ( Fig. 1g) . Notably, the interaction of endogenous p53 and SET was easily detected in unstressed cells; however, upon DNA damage, despite increased p53 levels, the p53-SET interaction was largely diminished, probably owing to the induction of CTD acetylation (Fig. 1h ). Moreover, chromatin immunoprecipitation (ChIP) assays revealed that the recruitment of SET to the promoter of p53 targets was largely inhibited ( Fig. 1i and Extended Data Fig. 1i-k) . Together, these data indicate that SET acts as a transcriptional co-repressor of p53. However, acetylation of the CTD upon DNA damage leads to abrogation of this repression through disruption of the p53-SET interaction (Fig. 1j ).
We further investigated whether inactivation of SET influences the activities of p53 in human cancer cells. RNA-interference-mediated depletion of SET markedly elevated the expression of p53 targets, such as cyclin dependent kinase inhibitor 1A (CDKN1A, also known as p21) and p53 upregulated modulator of apoptosis (PUMA, also known as Bcl-2-binding component 3), without affecting the steadystate levels of endogenous p53 in HCT116 colorectal carcinoma cells ( Fig. 2a ). Similar effects were obtained in other human cancer cell lines that express wild-type p53, including MCF7 (breast carcinoma), U2OS (osteosarcoma), H460 (lung carcinoma) and SU-DHL-5 (B-cell lymphoma) ( Fig. 2b) . Moreover, this induction of p21 and PUMA expression was completely abrogated in isogenic HCT116 p53 −/− cells (Fig. 2c) , indicating that the SET-mediated effects are p53-dependent. Further analysis of U2OS and p53-null U2OS cells that had SET knocked down identified a number of p53 targets that were upregulated upon inactivation of SET in a p53-dependent manner; SET knockdown induced p53-dependent cell growth repression in those cells (Extended Data Figs 2a-c, 3a, b). To examine the effect of SET on p53-mediated tumour suppression, we tested whether SET depletion affected cell growth in xenograft tumour models in immunodeficient mice (NU/NU). SET knockdown strongly suppressed tumour growth of HCT116 cells, but not isogenic HCT116 p53 −/− cells ( Fig. 2d ). Moreover, the p53-dependent effects were further validated in HCT116 p53 knockout cells generated by the CRISPR/Cas9-mediated genome editing technique (Extended Data Fig. 3c-e ). These data indicated that the p53-SET interaction is crucial for the tumour growth suppression induced by p53.
As SET had no apparent effect on protein stability, DNA binding or acetylation levels of p53 (Extended Data Fig. 4a -c), we examined whether SET suppressed p53-mediated transactivation by affecting chromatin modifications at p53 target promoters. ChIP analysis revealed that SET depletion significantly increased the acetylation levels of H3K18 and H3K27 at the promoters of p21 and PUMA in a   TAD  PRD  DBD  TD  CTD   1   p53   Biotin   97  300  364  393  42 63  100  324  355   370  372 373  381 382  386 CTD Acetylated p53 (Ac): Ac Ac Ac Ac Ac Ac 
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HCT116 cells without affecting H3K9, H3K14, H4K16 or inducing pan-H4 acetylation ( Fig. 2e and Extended Data Fig. 4d ). p300/CBP, which target H3K18 and H3K27 acetylation in vivo 16, 17 , act as a key co-activators of p53-mediated transcriptional activation [18] [19] [20] . We tested whether SET suppressed p300/CBP-mediated acetylation of H3K18 and H3K27, as SET had no obvious effect on the recruitment of p300/CBP (Extended Data Fig. 4e ). Indeed, in vitro acetylation assays revealed that SET effectively suppressed p300-dependent acetylation of H3K18 and H3K27 ( Fig. 2f ) and these findings were further verified for p53 target promoters by ChIP analysis (Fig. 2g and Extended Data Fig. 4f ). Together, these data indicate that SET represses p53-mediated transactivation by inhibiting p300/CBP-dependent acetylation of H3K18 and H3K27 on p53 target promoters ( Fig. 2h ).
Numerous studies have indicated that lysine acetylation often creates docking sites for 'reader' proteins that possess a bromodomain, a structural motif that forms a recognition surface for acetylated lysine 5, 6 . Our analysis of the p53-SET interaction suggests that the acidic domain of SET serves as a 'converse reader' that binds the lysine-rich CTD of p53 in a manner that can be specifically abrogated upon acetylation of these lysine residues. To further evaluate this model, we tested whether p53 interacts with other proteins in a similar manner. Several transcription cofactors known to interact directly with p53, including VPRBP, DAXX and PELP1 (refs. 7-9), also contain acidic domains similar to that of the SET protein ( Fig. 3a and Extended Data Fig. 5a ). Their acidic domains also readily bound unacetylated, but not acetylated, p53 CTD ( Fig. 3b-d ). Similar results were also obtained when the full-length proteins of VPRBP, DAXX and PELP1 were tested (Extended Data Fig. 5b ). More importantly, the interactions of VPRBP, DAXX and PELP1 with wild-type p53, but not the acetylation-deficient p53 KR mutant, were inhibited by CBP-induced acetylation in human cells (Extended Data Fig. 5c-e ).
Previous studies showed that SET also regulates the activities of several other cellular factors, including histone H3, KU70 and FOXO1, through direct interactions with these proteins [21] [22] [23] . Notably, the binding region of all three proteins contains a lysine-rich domain (KRD) similar to the CTD of p53 ( Fig. 3e ). These lysine residues have also been reported to be acetylated in vivo [24] [25] [26] . To test whether SET-mediated interactions with these factors are also regulated by acetylation, we performed in vitro binding assays of the acidic domain of SET with unacetylated or acetylated KRDs of H3, KU70 and FOXO1. The acidic domain of SET interacted with unacetylated, but not acetylated, KRDs of H3, KU70 and FOXO1 ( Fig. 3f -h). Similar results were also obtained when the full-length SET protein was used in the binding assays (Extended Data Fig. 5f -h), suggesting that the interaction of SET with H3, KU70 and FOXO1 were abrogated by acetylation in a manner analogous to that of p53 binding to SET. Since VPRBP, DAXX and PELP1 have also been implicated in transcription regulation, we investigated whether these factors could interact with H3 in a similar manner. VPRBP, DAXX and PELP1 specifically bound unacetylated H3 whereas, as expected, bromodomain proteins such BRD4 and BRD7 recognized only acetylated H3 (Extended Data Fig. 5i , j).
Our data indicate that this mechanism of acetylation-dependent regulation is widespread in nature. As the positive charge within the KRD can attract the negative charge of the acidic domain, these lysine clusters form a docking site for acidic-domain-containing regulators. However, upon acetylation, the positive charge of the lysine sidechains is neutralized, abolishing the docking site for the acidic-domaincontaining regulators. Conversely, deacetylation of these lysine residues reverses this effect and promotes the recruitment of acidic-domaincontaining regulators (Fig. 3i ). Thus, unlike bromodomain readers, which preferentially bind the acetylated forms of their cognate ligands, the acidic domain readers specifically recognize the unacetylated forms of their ligands.
To corroborate this notion, we compared the SET-binding properties of the acetylation-deficient mutant p53 KR with an acetylationmimicking mutant, p53 KQ (Extended Data Fig. 6a )., The p53 KR mutant, like unacetylated p53, strongly bound SET (Extended Data Fig. 6b ); conversely, the p53 KQ mutant, like acetylated p53, did not interact with SET. Similar results were also obtained upon analysis of the acetylation-modulated interactions of p53 with VPRBP, DAXX and PELP1 (Extended Data Fig. 6c -e).
To further determine the physiological importance of these interactions in vivo, we generated p53 KQ/KQ -mutant mice (Extended Data Fig. 7a-d ). Although heterozygous p53 +/KQ mice displayed normal postnatal development, p53 KQ/KQ homozygous mice showed neonatal lethality (Extended Data Fig. 7e ). All newborn p53 KQ/KQ pups were slightly smaller than their p53 +/+ littermates (Fig. 4a ), lacked milk in their stomachs and died within one day of birth, apparently owing to dehydration from lack of maternal nourishment. In addition, live p53 KQ/KQ mice also displayed uncoordinated movements, consistent with neurological impairments. Indeed, the brains of p53 KQ/KQ mice appeared smaller than those of p53 +/+ mice (Fig. 4b ).
Immunohistochemistry analysis of p53 KQ/KQ brain sections revealed a marked induction of cleaved caspase 3 staining without an obvious increase in p53 protein levels ( Fig. 4c and Extended Data Fig. 7f ), suggesting that the neurological defects of p53 KQ/KQ mice may reflect increased apoptosis due to deregulation of the p53 KQ protein. In accordance with this notion, the major apoptotic transcriptional targets of p53, namely Bax and Puma, were significantly upregulated in p53 KQ/KQ brain tissue ( Fig. 4d ). Indeed, various tissues of p53 KQ/KQ mice displayed distinct patterns of induction of different p53 target genes, suggesting tissue-specific activation of target genes by p53 KQ in vivo (Fig. 4d) .
The p53-SET interaction was readily detected in p53 +/+ , but not p53 KQ/KQ , mouse embryonic fibroblasts (MEFs) (Fig. 4e ). Similar results were also obtained for the other acidic-domain-containing cofactors (VPRBP, DAXX and PELP1), suggesting that the p53 KQ mutant recapitulates the activity of acetylated p53 in vivo. Moreover, p53 KQ/KQ MEFs displayed a severe proliferation defect ( Fig. 4f ) and exhibited clear signs of senescence, including a flat and enlarged morphology with large multinucleated nuclei and marked senescence-associated β-galactosidase (SA-β-Gal) staining (Fig. 4g, h and Extended Data Fig. 7g, h ). In addition, western blot analysis revealed an increase in the steady-state levels of p21 protein in p53 KQ/KQ MEFs (Fig. 4i ). To directly address the role of SET in vivo, we generated Set-mutant mice (Extended Data Fig. 8a, b) . Although the characterization of these mice was not complete (Extended Data Fig. 8c-e ), we prepared Set flox/flox MEFs for functional analysis. As shown in Fig. 4j , upon Cre-mediated Set deletion, the expression of p53 target genes, such as p21 and Puma, was markedly induced, indicating that SET is a critical regulator of p53 in vivo. Together, these data validate the key role of CTD acetylation in p53 activation in vivo.
Previous studies showed that a p53 KR knock-in mutant targeting the same CTD lysine residues does not significantly affect mouse development or p53 activity in mouse tissues or embryonic fibroblasts 27, 28 . Thus, loss of modifiable CTD lysines may neutralize the overall effect on p53 function by abrogating both the negative and positive effects of regulation through different types of CTD modification. Surprisingly, p53 KQ knock-in mice died shortly after birth with substantial p53 activation. Like p53 KR , p53 KQ also eliminates other types of modification on these lysine residues; however, p53 KQ mimics the acetylated form while p53 KR resembles unacetylated p53. Thus, the difference between the phenotypes of p53 KQ and p53 KR mutant mice underscores the role of CTD acetylation in vivo.
The acidic-domain-containing proteins in this study consist of a specific group of proteins that harbour long clusters of acidic amino acids. Searching the Uniprot database with our motif-finding algorithm 29 , we identified 49 polypeptides with highly acidic domains similar to SET, many of which are involved in transcriptional regulation and chromatin remodelling (Extended Data Table 1 ). In addition, by using the Species-Specific Prediction of lysine (K) Acetylation program (SSPKA) 30 , we also identified 49 proteins containing a cluster of lysine residues that can potentially bind these acidic domains in an acetylation-modulated manner (Extended Data Table 2 ). On the basis of our data, we propose that acetylation-mediated regulation, whereby acetylation of p53 abrogates its association with the acidicdomain-containing cofactors, can be expanded to a general mode of post-translational control for protein interactions that involve other acidic-domain-containing factors and their ligands, which can be modified by acetylation.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Uncropped blots can be found in Supplementary Fig. 1 .
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MethOdS General data reports. No statistical methods were used to pre-evaluate the sample size in this study. The experiments (including animal experiments) were not randomized. The investigators were not blinded to experiments. No samples/data were excluded except any obviously unhealthy xenografted mice. Cell culture, plasmid generation, transfection and reagent treatment. H1299, U2OS, MCF7, H460 and HCT116 cell lines were cultured in DMEM supplemented with 10% (vol/vol) FBS. The SU-DHL-5 cell line was cultured in IMDM supplemented with 10% (vol/vol) FBS. MEFs were cultured in DMEM supplemented with 10% (vol/vol) heat-inactivated FBS. All the cell lines were obtained from ATCC and have been proven to be negative for mycoplasma contamination. No cell lines used in this work were listed in the ICLAC database. The cell lines were freshly thawed from the purchased seed cells and were cultured for no more than 2 months. The morphology of cell lines was checked every week and compared with the ATCC cell line image to avoid cross-contamination or misuse of cell lines. SET stable knockdown cells were generated by lentivirus-based infection of shRNA. SET cDNA was purchased from Addgene (Plasmid number 24998) and the full-length cDNA or the various fragments were sub-cloned into pWG-F-HA, pCMV-Myc or PGEX-2TL vectors. Each p53 plasmid was generated by sub-cloning human p53 cDNA (including full-length or various fragments) into pWG-F-HA, pcDNA3.1 or PGEX-2TL vectors. The point-mutation constructs (including p53-KR and -KQ) were generated by using a site-directed mutagenesis Kit (Stratagene, 200521). Introduction of the expressing construct and siRNA transfection were performed by Lipofectamine 2000 (Invitrogen, 11668-019) according to the manufacturer's protocol. To transfer oligos into SU-DHL-5 cells, we used electroporation following the manufacturer's protocol (Lonza PBC3-00675). The DNA damage inducer doxorubicin was used at 1 μM for 24 h. The proteasome inhibitor epoxomicin was used at 100 nM for 6 h. Cells were treated with TSA (1 μM) and nicotinamide (5 mM) for 6 h to inhibit HDAC activity in the assays in which p53 acetylation needed to be maintained. Ad-GFP and Ad-Cre-GFP viruses were purchased from Vector Biolabs (Catalogue numbers 1761 and 1710). Mouse model. To generate the knock-in mice, W4/129S6 mouse embryonic stem (ES) cells (Taconic) were electroporated with a targeting vector containing homologous regions flanking the mouse p53 exon 11, in which all 7 lysines were mutated to glutamines (p53 KQ allele). A neomycin-resistance gene cassette flanked by two LoxP sites (LNL) was inserted into intron 10 to allow selection of targeted ES cell clones with G418. ES cell clones were screened by Southern blotting with EcoRI-digested genomic DNA, using a probe generated from PCR amplification in the region outside the homologous region in the targeting vector. The correctly targeted ES cell clones containing the K-to-Q mutations were injected into C57BL/6 blastocysts, which were then implanted into pseudopregnant females to generate chimaeras. Germ-line transmission was accomplished by breeding chimaeras with C57BL/6 mice. Subsequently, mice containing the targeted allele were bred with Rosa26-Cre mice to remove the LNL cassette and to generate mice with only the K-to-Q mutations. To confirm the mutations inserted in p53 +/KQ mice, we sequenced p53 cDNA derived from mRNA isolated from p53 +/KQ spleen. All seven K-to-Q mutations were confirmed and no additional mutations were found. The offspring were genotyped by PCR using the following primer set, forward: 5′-GGGAGGATAAACTGATTCTCAGA-3′, reverse: 5′-GATGGCTTCTACTATGGGTAGGGAT-3′.
To generate a Set conditional knockout mouse, exon 2 of the Set gene was floxed and deletion of exon 2 resulted in a frameshift and the truncation of the C-terminal domain. The targeting vector of Set contained 10 kb genomic DNA spanning exon 2; a neomycin-resistance gene cassette and loxP sites were inserted flanking exon 2. To increase targeting frequency, a diphtheria toxin A cassette was inserted at the 3′ end of the targeting vector to reduce random integration of the modified Set genomic DNA. A new BglII restriction site was also inserted to facilitate Southern blot screening. Of the 200 mouse ES cell clones screened, eight were identified to have integrated the floxed exon 2 by Southern blot using a 5′ probe, which detects a 14-kb band for the wild-type allele and an 11-kb band for the floxed exon 2 allele (Set flox ). Two of the clones were then injected into blastocysts to generate Set chimaera mice and they were bred to produce germ-line transmission of the floxed exon 2 allele. Set flox/+ mice were intercrossed to generate Set homozygous conditional knockout mice (Set flox/flox ).
Maintenance and experimental procedures of mice were approved by the Institutional Animal Care and Use Committee (IACUC) of Columbia University. In vitro binding assay. For the in vitro peptide binding assay: equal amounts of each synthesized biotin-conjugated peptide (made as column or as batch) were incubated with highly concentrated HeLa nuclear extract (NE) or purified proteins for 1 h or overnight at 4 °C. After washing with BC100 buffer (20 mM Tris-HCl pH 7.9, 100 mM NaCl, 10% glycerol, 0.2 mM EDTA, 0.1% triton X-100) three times, the binding components were eluted in high-salt buffer (20 mM Tris-HCl pH 7.9, 1,000 mM NaCl, 1% DOC, 10% glycerol, 0.2 mM EDTA, 0.1% triton X-100) or by boiling with 1 × Laemmli buffer for further analysis. For the in vitro GST-fusion protein binding assay: Escherichia coli containing GST or GST-fusion protein expressing constructs were grown in a shaking incubator at 37 °C until the OD 600 was about 0.6. Next 0.1 mM IPTG was added and the E. coli were incubated at 25 °C for 4 h or overnight, to induce GST or GST-fusion protein expression. After purification by GST·Bind Resin (Novagen, 70541), equal amounts of immobilized GST or GST-fusion proteins were incubated with other purified proteins for 1 h at 4 °C, followed by washing with BC100 buffer three times. The binding components were eluted by boiling with 1 × Laemmli buffer and were analysed by western blot. Co-immunoprecipitation assay (Co-IP). Whole cellular extracts (WCE) were prepared in BC100 buffer with sonication. Nuclear extract (NE) was prepared by sequentially lysing cells with HB buffer (20 mM Tris-HCl pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM PMSF, 1 × protease inhibitor (Sigma)) for the cytosolic fraction and BC400 buffer (20 mM Tris-HCl pH 7.9, 400 mM NaCl, 10% Glycerol, 0.2 mM EDTA, 0.5% triton X-100, 1 mM PMSF, 1 × protease inhibitor) for nuclear fraction. The salt concentration of NE was adjusted to 100 mM. 2 μg of the indicated antibody (or 20 μl Flag M2 Affinity Gel (Sigma, A2220)) was added into WCE or NE and incubated overnight at 4 °C, followed by addition of 20 μl protein A/G agarose (Santa Cruz, sc-2003; only for IP with unconjugated antibodies mentioned above) for 2 h. After washing with BC100 buffer three times, the binding components were eluted using Flag peptide (Sigma, F3290), 0.1% trifluoroacetic acid (TFA, Sigma, 302031) or by boiling with 1 × Laemmli buffer, and were analysed by western blot. Purification of Ub-, Sumo-or Nedd-p53 conjugates from cells. For preparation of Ub-p53: H1299 cells were co-transfected with p53, MDM2 and 6 × HA-Ub (human) expressing plasmids for 48 h. The cells were lysed with Flag lysis buffer (50 mM Tris-HCl pH 7.9, 137 mM NaCl, 10 mM NaF, 1 mM Na 3 VO 4 , 10% glycerol, 0.5 mM EDTA, 1% triton X-100, 0.2% sarkosyl (sodium lauroyl sarcosinate), 0.5 mM DTT, 1 mM PMSF, 1 × protease inhibitor) and total Ub-conjugated proteins were purified by anti-HA-agarose (Sigma, A2095) and eluted by 1 × HA peptide (Sigma I2149). For the preparation of Sumo-p53 or Nedd-p53: H1299 cells were co-transfected with p53, MDM2 (only for Nedd-p53 preparation) and 6 × His-HA-Sumo1 (human) or 6 × His-HA-Nedd8 (human) expressing plasmids for 48 h. The cells were lysed with guanidine lysis buffer (6 M guanidin-HCl, 0.1 M Na 2 HPO 4 , 6.8 mM NaH 2 PO 4 , 10 mM Tris-HCl pH 8.0, 0.2% triton-X100, freshly supplemented with 10 mM β-mercaptoethanol and 5 mM imidazole) with mild sonication. After overnight pull-down by Ni + -NTA agarose (Qiagen 30230), the binding fractions were sequentially washed with guanidine lysis buffer, urea buffer I (8 M urea, 0.1 M Na 2 HPO 4 , 6.8 mM NaH 2 PO 4 , 10 mM Tris-HCl pH 8.0, 0.2% triton-X100, freshly supplemented with 10 mM β-mercaptoethanol and 5 mM imidazole) and urea buffer II (8 M urea, 18 mM Na 2 HPO 4 , 80 mM NaH 2 PO 4 , 10 mM Tris-HCl pH 6.3, 0.2% triton-X100, freshly supplemented with 10 mM β-mercaptoethanol and 5 mM imidazole). Precipitates were eluted in elution buffer (0.5 M imidazole, 0.125 M DTT). All purified proteins were dialysed against BC100 buffer before use in the subsequent pull-down assay. After the pull-down assay, the interaction between SET and each p53-conjugate was detected by western blot with anti-p53 (DO-1) antibody. Mass spectrometry assay. The protein complex was separated by SDS-PAGE and stained with GelCode Blue reagent (Pierce, 24592). The visible band was cut and digested with trypsin and then subjected to liquid chromatography (LC)-MS/MS analysis. Luciferase assay. A firefly reporter (p21-Luci reporter) and a Renilla control reporter were co-transfected with indicated constructs in H1299 cells for 48 h and the relative luciferase activity was measured by dual-luciferase assay protocol (Promega, E1910). Electrophoretic mobility shift assay. Highly purified p53 or SET was incubated with a 32 P-labelled probe (160 bp) containing the p53-binding element of the p21 promoter in 1× binding buffer (10 mM HEPES, pH 7.6, 40 mM NaCl, 50 μM EDTA, 6.25% glycerol, 1 mM MgCl 2 , 1 mM spermidine, 1 mM DTT, 50 ng μl −1 BSA, 5 ng μl −1 sheared single strand salmon DNA) for 20 min at room temperature (RT). For the super-shift assay, α-p53 or α-SET antibody was pre-incubated with purified p53 and SET in the reaction system without probe for 30 min at RT and then the probe was added for a further 20 min. The complex was analysed by 4% Tris-Borate-EDTA buffer-polyacrylamide gel electrophoresis (TBE-PAGE) and visualized by autoradiography. The probe was obtained by PCR, labelled by T4 kinase (NEB, M0201S) and purified by Bio-Spin column (Bio-Rad, 732-6223). Chromatin immunoprecipitation (ChIP) assay. Cells were fixed with 1% formaldehyde for 10 min at room temperature and lysed with ChIP lysis buffer (50 mM Tris-HCl pH 8.0, 5 mM EDTA, 1% SDS, 1× protease inhibitor) for 10 min at 4 °C.
After sonication, the lysates were centrifuged, and the supernatants were collected and pre-cleaned by salmon sperm DNA saturated protein A agarose (Millipore, in dilution buffer (20 mM Tris-HCl pH 8.0, 2 mM EDTA, 150 mM NaCl, 1% triton X-100, 1× protease inhibitor) for 1 h at 4 °C. The pre-cleaned lysates were aliquoted equally and incubated with indicated antibodies overnight at 4 °C. Saturated protein A agarose was added into each sample and incubated for 2 h at 4 °C. The agarose was washed with TSE I (20 mM Tris-HCl pH 8.0, 2 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% triton X-100), TSE II (20 mM Tris-HCl pH 8.0, 2 mM EDTA, 500 mM NaCl, 0.1% SDS, 1% triton X-100), buffer III (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.25 M LiCl, 1% DOC, 1% NP40), and buffer TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA), sequentially. The binding components were eluted in 1% SDS and 0.1 M NaHCO 3 and reverse cross-linkage was performed at 65 °C for at least 6 h. DNA was extracted using the PCR purification Kit (Qiagen, 28106). Real-time PCR was performed to detect relative enrichment of each protein or modification on indicated genes. Cell growth assay. Approximately 10 5 MEFs or U2OS cells, as indicated in each figure, were seeded into 6-well plates with three replicates. Their cell growth was monitored on consecutive days, as indicated, by using the Countess automated cell counter (Invitrogen) or by staining with 0.1% crystal violet. For quantitative analysis of the crystal violet staining, the crystal violet was extracted from cells using 10% acetic acid and the relative cell number was measured by detecting the absorbance at 590 nm. Xenograft model. 10 6 HCT116-derived cells, as indicated in each figure, were mixed with Matrigel (Corning, 354248) in a 1:1 ratio in a total volume of 200 μl. The cell-matrix complex was subcutaneously injected into nude mice (NU/NU; 8 weeks old; female; strain 088; Charles River). After 3 weeks, the mice were killed and weight of the tumours was measured. The experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Columbia University. None of the experiments were exceeded the limit for tumour burden (10% of total bodyweight or 2 cm in diameter). RT-qPCR. Total RNA was extracted by TRIzol (Invitrogen, 15596-026) and precipitated in ethanol. 1 μg of total RNA was reverse transcribed into cDNA using the SuperScript III First-Strand Synthesis SuperMix (Invitrogen, 11752-50). The relative expression of each target was measured by qPCR and the data were normalized by the relative expression of GAPDH or ActB. Immunohistochemistry (IHC). FFPE sections of mouse brain tissue samples were stained with indicated antibodies and visualized by DAB exposure. Protein purification. The Flag-tagged p53 or SET construct was transfected into H1299 cells for 48 h and the cells were lysed in Flag lysis buffer. After centrifugation, the Flag M2 Affinity Gel was added to supernatant and incubated for 1h at 4 °C. After washing with Flag lysis buffer six times, the purified proteins were eluted with Flag peptide. For purification of acetylated p53, the construct CBP was co-transfected with the p53 vector for 48 h. TSA and nicotinamide were added into the medium for the last 6 h and the cells were harvested in Flag lysis buffer supplemented with TSA and nicotinamide. The C-terminal unacetylated p53 was removed by p53-PAb421 antibody and then the acetylated p53 was purified as described above. In vitro acetylation assay. 0.5 μg recombinant H3 was incubated with 20 ng purified p300 in 1× HAT buffer (50 mM Tris-HCl, pH 7.9; 1 mM DTT; 10 mM sodium butyrate, 10% glycerol) containing 0.1 mM Ac-CoA for 30 min at 30 °C. After the reaction, the products were assayed by western blot with indicated antibodies. To measure the effect of SET on p300-mediated H3 acetylation, H3 and purified SET (1 μg) were pre-incubated in 1× HAT buffer for 20 min at room temperature before addition of the other components (p300 and Ac-CoA) for the subsequent in vitro acetylation assay. Generation of the p53 knockout (p53-KO) cell line using the CRISPR/Cas9 technique. Cells were transfected with constructs expressing Cas9-D10A (Nickase) and control sgRNAs or sgRNAs targeting p53 exon3 (Santa Cruz: sc-437281 for control; sc-416469-NIC for targeting of p53). After 48 h of transfection, cells were suspended, diluted and re-seeded to ensure single clone formation. More than 30 clones were picked up and the expression of p53 in each single clone was evaluated by western blot with both α-p53 (DO-1) and α-p53 (FL-393) antibodies. Further verification of positive clones was done by sequencing the genomic DNA to make sure that the functional genomic editing occured (insertion or deletion-mediated frame-shift of the p53 open reading frame (ORF)). Two (U2OS) or three (HCT116) clones were finally selected for subsequent experiments. The p53 knockout-mediated effect was verified to be reproducible in these independent clones. The targeting sequences of p53 loci for the sgRNAs were: 1) TTGCCGTCCCAAGCAATGGA; 2) CCCCGGACGATATTGAACAA. RNA-seq. U2OS (CRISPR Ctr or CRISPR p53-KO) cells were transfected with control siRNA or SET-specific siRNA (three oligos) for 4 days. Each sample group had at least two biological replicates. Total RNA was prepared using TRIzol (Invitrogen, 15596-026). The RNA quality was evaluated by Bioanalyzer (Agilent) and confirmed that the RIN > 8. Before performing RNA-seq analysis, a small aliquot of each sample was analysed by RT-qPCR to confirm SET knockdown efficiency. RNA-seq analysis was performed at the Columbia Genome Center. Specifically, from total RNA samples, mRNAs were enriched by poly-A pull-down and then processed for library preparation by using the Illumina TruSeq RNA prep kit (Illumina RS-122-2001). Libraries were then sequenced using the Illumina HiSeq2000. Samples were multiplexed in each lane and yielded targeted number of single-end 100-bp reads for each sample. RTA (Illumina) was used for base calling and bcl2fastq (version 1.8.4) was used for converting BCL to fastq format, coupled with adaptor trimming. Reads were mapped to a reference genome (Human: NCBI/build37.2) using TopHat (version 2.0.4). Relative abundance of genes and splice isoforms were determined using Cufflinks (version 2.0.2) using the default settings. Differentially expressed genes were tested under various conditions using DEseq, an R package based on a negative binomial distribution that models the number reads from RNA-seq experiments and tests for differential expression. To further analyse the differentially expressed genes in a more reliable interval, the following filter strategies were applied: 1) the average of FPKM (Fragments per kilobase of transcript per million mapped reads) in either sample group exceeded 0.1; 2) the fold change between the CRISPR Ctr/si-Ctr group and the CRISPR Ctr/si-SET group exceeded 2; 3) the P value between the CRISPR Ctr/si-Ctr group and the CRISPR Ctr/si-SET group < 0.01.
To retrieve potential p53 target genes which were repressed by SET in a p53dependent manner, we searched the filtered RNA-seq results using the following strategies: 1) the expression level in the CRISPR Ctr/si-SET group was at least 2-fold higher than that in the CRISPR Ctr/si-Ctr group; 2) the expression level in the CRISPR Ctr/si-SET group was at least 2-fold higher than that in the CRISPR p53-KO/si-SET group. The filtered genes which were also verified as p53 target genes from the literature were collected and presented as a heatmap. Bioinformatic analysis. For the discovery of acidic domains in the human proteome: our motif-finding algorithm initially searched for sequence motifs with a minimum acidic composition of 76% using a sliding window of 36 residues, as dictated by experimental results. Motifs found to be partially overlapping were merged into single motifs. Flanking non-acidic residues were subsequently cropped-out from the final motif. Motif discovery was carried out using the UniProt database, which contains 20,187 canonical human proteins, that have been manually annotated and reviewed. For prediction of proteins that bound acidic domaincontaining proteins and were regulated by acetylation: we identified proteins that can potentially bind long acidic domains in a similar way to p53: using a K-rich region whose binding properties can be regulated by acetylation. We used the training set assembled in SSPKA, which combines lysine acetylation annotations from multiple resources obtained either experimentally or in the scientific literature. This dataset individually lists all annotated acetylation sites for a given protein. We generated acetylation motifs with multiple acetylation sites by clustering those sites found to within a maximum distance of 11 residues in sequence. Following this, we searched for acetylation motifs with five or more lysines where at least three of them are annotated as acetylation sites. Statistical analysis. Results are shown as means ± s.d. Statistical significance was determined by using a two-tailed, unpaired Student t-test in all figures except those described below. In Fig. 1g , significance was determined by one-way ANOVA with a Bonferroni post hoc test. In Fig. 2d and g and Extended Data Figs 2c, 3b, d, 4f and 7h, statistical significance was measured by two-way ANOVA with a Bonferroni post hoc test. All statistical analysis was performed using GraphPad Prism software. P < 0.05 was denoted as statistically significant.
Letter reSeArCH extended data table 2 | A list of human proteins containing Krds with at least five lysines where three or more lysines are annotated as acetylation sites in the SSPKA database Each protein is described by its UniProt accession code and protein name (1 st and 2 nd column, respectively). Acetylated motifs are described by the position of their annotated acetylation sites within the coding sequence and their sequence (3 rd and 4 th column, respectively).
